Comments
Omnicare Drugs India, an arm of the UAE-based Neopharma LLC, and Japan’s ASKA Pharmaceuticals have inked an agreement to establish a joint venture (JV) in India.
The proposed JV unit, which will manufacture and market pharmaceuticals to a ‘large global market’, will come up in JN Pharma City, Visakhapatnam, at an investment of ₹350 crore.
The unit, to be operational by 2020, will manufacture oral solid dosage forms, oral liquids and topical preparations, and will have a peak capacity to manufacture three billion tablets a year.
“We are entering into a strategic relationship with ASKA Pharmaceuticals to accelerate growth in regulated markets of the US and the European Union and in Africa and Asia. The joint venture will be highly complementary as it will further strengthen Neopharma’s presence in tough markets like India and Japan, which are among the world’s largest pharma markets,’’ said N Suresh Kumar, COO, Neopharma, in a release issued here.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.